{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-012514","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.941705+00:00","generated_at":"2026-05-17T05:17:13.871122+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed","bullets":["LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).","LOTIS-5 Phase 3 trial fully enrolled; topline data expected 1H 2026 for potential sBLA submission.","ZYNLONTA Phase 2 IIT in r/r MZL showed 69.2% CR and 84.6% ORR (N=26 evaluable); CR maintained in 17/18 patients.","PSMA-targeting ADC progresses IND-enabling activities; seeking research collaborations.","Cash runway expected into 2028; company continues to grow ZYNLONTA revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-012514","json":"https://secwatch.observer/filing/0000950103-25-012514.json","markdown":"https://secwatch.observer/filing/0000950103-25-012514.md","text":"https://secwatch.observer/filing/0000950103-25-012514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325012514/0000950103-25-012514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325012514/dp235214_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:17:13.871122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}